EZR and breast cancer: Our findings indicate that ezrin is an important modulator of chemotherapy resistance in breast cancer and that anti-ezrin therapy can sensitize metastatic breast cancer cells to DOX or DTX in preclinical models of neoadjuvant or neoadjuvant plus adjuvant treatment.